IL3RA and neoplasm: This was achieved by decitabine through inhibition of DNMT3A and DNMT1 expression, increased DNA hypomethylation and upregulated expression of genes that favored naïve and memory T cells differentiation, resulting in enhanced CD123 CAR-T cells anti-tumor responses (141).